BNT211 already has orphan drug and fast-track ... at approximately 35%. BioNTech and Regeneron are competing with rivals Moderna and MSD in the mRNA melanoma jab category, with the latter a ...
Pfizer and BioNTech have been among the leaders in the race to bring a combined COVID-19 and influenza vaccine to market, but have stumbled in the final straight. The companies reported mixed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback